Keyword search (4,164 papers available)

"Beauchet O" Authored Publications:

Title Authors PubMed ID
1 Teleconsultations for mental health: Recommendations from a Delphi panel Manera V; Partos C; Beauchet O; Benoit M; Dupetit B; Elbaum J; Fabre R; Gindt M; Gros A; Guerchouche R; Klöppel S; König A; Martin A; Mouton A; Pancrazi MP; Politis A; Robert G; Sacco G; Sacconi S; Sawchuk K; Solari F; Thiebot L; Trimarchi PD; Zeghari R; Robert P; 37655117
ENCS
2 Alzheimer's early detection in post-acute COVID-19 syndrome: a systematic review and expert consensus on preclinical assessments Vandersteen C; Plonka A; Manera V; Sawchuk K; Lafontaine C; Galery K; Rouaud O; Bengaied N; Launay C; Guérin O; Robert P; Allali G; Beauchet O; Gros A; 37416323
CONCORDIA
3 Benefits of a 3-month cycle of weekly virtual museum tours in community dwelling older adults: Results of a randomized controlled trial Beauchet O; Matskiv J; Galery K; Goossens L; Lafontaine C; Sawchuk K; 36052331
CONCORDIA
4 Frailty, e-health and prevention of late-onset Alzheimer disease and related disorders: it is time to take action Beauchet O; Galery K; Lafontaine C; Sawchuk K; Plonka A; Gros A; Allali G; 35334089
CONCORDIA
5 Guidelines for Gait Assessments in the Canadian Consortium on Neurodegeneration in Aging (CCNA). Cullen S, Montero-Odasso M, Bherer L, Almeida Q, Fraser S, Muir-Hunter S, Li K, Liu-Ambrose T, McGibbon CA, McIlroy W, Middleton LE, Sarquis-Adamson Y, Beauchet O, McFadyen BJ, Morais JA, Camicioli R, Canadian Gait and Cognition Network 29977431
ENCS
6 Consensus on Shared Measures of Mobility and Cognition: From the Canadian Consortium on Neurodegeneration in Aging (CCNA). Montero-Odasso M, Almeida QJ, Bherer L, Burhan AM, Camicioli R, Doyon J, Fraser S, Muir-Hunter S, Li KZH, Liu-Ambrose T, McIlroy W, Middleton L, Morais JA, Sakurai R, Speechley M, Vasudev A, Beauchet O, Hausdorff JM, Rosano C, Studenski S, Verghese J, Canadian Gait and Cognition Network 30101279
PERFORM
7 Brain gray matter volume associations with gait speed and related structural covariance networks in cognitively healthy individuals and in patients with mild cognitive impairment: A cross-sectional study. Beauchet O, Montembeault M, Barden JM, Szturm T, Bherer L, Liu-Ambrose T, Chester VL, Li K, Helbostad JL, Allali G, Canadian Gait Consortium 31075383
PSYCHOLOGY
8 Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial. Beauchet O, Barden J, Liu-Ambrose T, Chester VL, Annweiler C, Szturm T, Grenier S, Léonard G, Bherer L, Allali G, Canadian Gait Consortium 27568453
PERFORM
9 Association Between Falls and Brain Subvolumes: Results from a Cross-Sectional Analysis in Healthy Older Adults. Beauchet O, Launay CP, Barden J, Liu-Ambrose T, Chester VL, Szturm T, Grenier S, Léonard G, Bherer L, Annweiler C, Helbostad JL, Verghese J, Allali G, Biomathics and Canadian Gait Consortium 27785698
PERFORM

 

Title:Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.
Authors:Beauchet O,  Barden J,  Liu-Ambrose T,  Chester VL,  Annweiler C,  Szturm T,  Grenier S,  Léonard G,  Bherer L,  Allali G,  Canadian Gait Consortium
Link:https://www.ncbi.nlm.nih.gov/pubmed/27568453?dopt=Abstract
DOI:10.1007/s40266-016-0391-0
Publication:Drugs & aging
Keywords:
PMID:27568453 Category:Drugs Aging Date Added:2019-04-15
Dept Affiliation: PERFORM
1 Department of Medicine, Division of Geriatric Medicine, Sir Mortimer B. Davis-Jewish General Hospital and Lady Davis Institute for Medical Research, McGill University, 3755 chemin de la Côte-Sainte-Catherine, Montréal, QC, H3T 1E2, Canada. olivier.beauchet@mcgill.ca.
2 Faculty of Medicine, McGill University, Montreal, QC, Canada. olivier.beauchet@mcgill.ca.
3 Centre of Excellence on Aging and Chronic Diseases of McGill Integrated University Health Network, Montreal, QC, Canada. olivier.beauchet@mcgill.ca.
4 Faculty of Kinesiology and Health Studies, Neuromechanical Research Centre, University of Regina, Regina, SK, Canada.
5 Aging, Mobility and Cognitive Neuroscience Laboratory, University of British Columbia, Vancouver, BC, Canada.
6 Andrew and Marjorie McCain Human Performance Laboratory, Faculty of Kinesiology, Richard J. Currie Center, University of New Brunswick, Fredericton, NB, Canada.
7 Department of Neuroscience, Division of Geriatric Medicine, Angers University Hospital, Angers, France.
8 University Memory Clinic of Angers, Angers, France.
9 UPRES EA 4638, University of Angers, UNAM, Angers, France.
10 Department of Medical Biophysics, Center for Functional and Metabolic Mapping, Schulich School of Medicine and Dentistry, Robarts Research Institute, University of Western Ontario, London, ON, Canada.
11 Department of Physical Therapy, College of Rehabilitation Sciences, University of Manitoba, Winnipeg, MB, Canada.
12 Centre de recherche, Institut universitaire de gériatrie de Montréal (CRIUGM), Montréal, QC, Canada.
13 Institut universitaire de gériatrie de Sherbrooke (IUGS), Montréal, QC, Canada.
14 PERFORM Centre and Department of Psychology, Concordia University, Montreal, QC, Canada.
15 Department of Neurology, Geneva University Hospital and University of Geneva, Geneva, Switzerland.

Description:

Anti-Dementia Drugs, Gait Performance and Mental Imagery of Gait: A Non-Randomized Open-Label Trial.

Drugs Aging. 2016 09;33(9):665-73

Authors: Beauchet O, Barden J, Liu-Ambrose T, Chester VL, Annweiler C, Szturm T, Grenier S, Léonard G, Bherer L, Allali G, Canadian Gait Consortium

Abstract

BACKGROUND: Few studies have examined the effect of anti-dementia drugs (i.e., acetylcholinesterase inhibitors and N-methyl-D-aspartate receptor antagonists) on gait performance. Past studies have focused on the stride time (i.e., gait cycle duration) but not on the mental imagery of gait.

OBJECTIVES: To compare mental imagery of gait and spatiotemporal gait parameters in patients with dementia [i.e., Alzheimer's disease (AD) and non-AD] before and after the use of anti-dementia drugs (i.e., acetylcholinesterase inhibitors and memantine) and in controls (i.e., patients with dementia who did not take anti-dementia drugs).

METHODS: A total of 112 patients (mean age 82.5 ± 4.2 years, 68.8 % female) with mild-to-moderate AD and non-AD dementia were included in this non-randomized open-label trial (n = 56 in the Intervention group, and n = 56 in the Control group matched for age, sex, and stage and type of dementia) nested in a cohort study (mean follow-up 238.5 ± 79.8 days). Mental imagery of gait was assessed with the actual and imagined Timed Up and Go tests (aTUG and iTUG) and the difference between aTUG and iTUG (i.e., delta-TUG). Spatiotemporal gait parameters were measured with the GAITRite(®) system during normal walking.

RESULTS: Participants in the Intervention group had a longer iTUG time (p < 0.001) and a lower delta-TUG value (p = 0.001) at the follow-up compared with those in the Control group. There was a significant increase in iTUG (p = 0.001) and decrease in delta-TUG (p < 0.001) from baseline to the follow-up only in the Intervention group. Multiple linear regression showed that the use of anti-dementia drugs was associated with a longer iTUG time and a lower delta-TUG value (best performance, p < 0.002).

CONCLUSIONS: Our findings showed an improvement in mental imagery of gait with the use of anti-dementia drugs, but no changes in actual gait performance.

TRIAL REGISTRATION: NCT01315704.

PMID: 27568453 [PubMed - indexed for MEDLINE]




BookR developed by Sriram Narayanan
for the Concordia University School of Health
Copyright © 2011-2026
Cookie settings
Concordia University